novavax vaccine - Search News

Order byBest matchMost fresh

Novavax scores narrower Covid vaccine approval

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who hav...

· 3d · on MSN

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

STAT · 19h

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

· 22h

Here's what to know about the FDA's COVID-19 vaccine changes

COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration.

· 1d

FDA panel recommends keeping COVID shots targeted to same strain as last year

· 1d

Trump's FDA Has Axed COVID Boosters For Most People — And Medical Experts Are Deeply Worried

· 1d

With vaccine approval process set to change, FDA advisers leave wiggle room in annual Covid-19 shot recommendations

Several of the committee members asked at Thursday’s meeting about the FDA’s new vaccine approval framework. Some expressed concern that changing the strain targeted in this year’s vaccine might decr...

· 20h

COVID shots should target newer strains of JN.1 variant, US FDA advisers say

Health.com · 1d

FDA to Limit Access to COVID Vaccines—What This Means For You

4don MSN

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some investor concerns over the future of the shot.

Trump’s FDA just changed COVID vaccine rules for 2025 — will you still qualify for boosters under the new guidelines?

FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and high-risk individuals. While the FDA met to decide if vaccine formulas should change for fall 2025,

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,